Powered by
-
GSK Stock Chart
Historical GSK Prices
GLAXOSMITHKLINE ADR Stock Analysis
Rating: Sell
Total Grade: D
Analysis Breakdown
| GSK Stock Grade: | D |
| Fundamental Grade: | D |
| Quantitative Grade: | D |
| GSK Earnings | |
| Earnings Growth: | D |
| Earnings Momentum: | C |
| Earnings Surprises: | C |
| Analyst Earnings Revisions: | C |
| GSK Financial Information | |
| Sales Growth: | C |
| Operating Margin Growth: | D |
| Cash Flow: | B |
| Return on Equity: | F |
GLAXOSMITHKLINE ADR Stock: Weekly View
| This Week: | D |
|---|---|
| Last Week: | D |
| Two Weeks Ago: | C |
GSK Stock predictions, Articles, and GLAXOSMITHKLINE ADR News
- From InvestorPlace
- From the Web
-
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs - May 18, 2018
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are. Continue…
-
10 Risky (But Rewarding) Small-Cap Stocks to Buy Now - April 27, 2018
These ten stocks aren't exactly household names, but they each deserve a spot in a list of small-cap stocks to buy now for traders that can deal with the risk for the potential of high reward. Continue…
-
GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss - April 25, 2018
GlaxoSmithKline (GSK) stock was down on Wednesday following the release of an earnings report that misses estimates for the first quarter of 2018. Continue…
-
7 Dividend Stocks That May Be Hurting Your Retirement - April 25, 2018
Often there are signs leading up to dividend stocks cutting their payouts. If you own any of these 7 you'd be better off moving your money elsewhere. Continue…
-
3 Emerging Technologies Set to Transform the Pharma World - April 5, 2018
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by.... Continue…
-
GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal - March 27, 2018
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018. Continue…
-
The 3 Safest Dividend Stocks for International Exposure - March 22, 2018
International dividend stocks should make up a hefty portion of your portfolio, as you need them to smooth out the sort of stateside volatility we're experiencing right now. Continue…
-
Pfizer Inc. Stock Owners Should Brace for This Possibility - February 7, 2018
Reports show that not many companies are interested in Pfizer's (PFE) consumer health arm. Here's what they're balking at and what it means for PFE stock owners. Continue…
-
GlaxoSmithKline’s (GSK) Upgraded to Hold - December 8, 2017
Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Hold. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. The shares have been upgraded from a Sell to a Hold in the last week. Continue…
-
Metrics for Quant Score Make GlaxoSmithKline (GSK) a Sell - November 24, 2017
GlaxoSmithKline Plc (NYSE:GSK) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 781 company GICS Health Care sector. GSK has a market value of $85.7 billion which is in the top 10% of its industry group. The ranking for GSK by Portfolio Grader places it 87 among the 133 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 503 among the 781 companies in the sector, and number 3,192 in the nearly 5,000 company Portfolio Grader universe. Continue…
